Lung Cancer News
Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.
Researchers are evaluating whether adding a dendritic cell-based p53 vaccine to combination checkpoint inhibition will improve outcomes among patients with recurrent SCLC.
Researchers retrospectively analyzed the outcomes of 78 patients with stage IV lung SCC who were treated with gemcitabine plus cisplatin as first-line therapy.
Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.
PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.
FDA Accepts Supplemental New Drug Application for Osimertinib as First-line Treatment in EGFR-mutant NSCLC
Data from FLAURA may position osimertinib as the first-line standard of care for patients with EGFR-mutant NSCLC.
Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.
Data from previous studies suggest that adjuvant chemotherapy and PORT may improve patient outcomes, but the optimal sequence of administration was previously unestablished.
Researchers are evaluating whether Ad5-yCD/mutTKSR39rep-ADP, an oncolytic adenovirus, can help to improve outcomes among patients with inoperable stage I/IIA NSCLC.
SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.
Researchers are evaluating the safety and efficacy of pembrolizumab in combination with a synthetic long peptide vaccine among patients with non-small cell lung cancer.
Researchers are assessing the safety and efficacy of lorlatinib among patients with ROS1 and ALK mutation-positive NSCLC that has metastasized to the CNS.
Researchers are evaluating the safety and efficacy of a vaccine for patients with resectable NSCLC.
Researchers are assessing the efficacy of neoadjuvant pembrolizumab with or without low-dose SRT among patients with stage I to IIIA NSCLC who plan to undergo surgical resection.
Researchers enrolled 222 patients with completely resected stage II-IIIA (N1-N2) NSCLC to receive adjuvant gefitinib or cisplatin plus vinorelbine.
Researchers evaluated the biopsies and outcomes of 5 patients with an EGFR-activating mutation who were initially treated with a first- or second-generation EGFR-TKI.
Investigators randomly assigned 1501 patients with completely resected stage IB to IIIA NSCLC to receive chemotherapy alone or chemotherapy plus bevacizumab.
In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.
The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.
Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Hyperthermia Plus Chemotherapy Improves Survival in Soft Tissue Sarcoma
- Survey May Help To Identify Patients With Cancer at Risk of HBV Reactivation
- Fish Consumption and Cancer
- Socioeconomic Status May Preclude Elderly Patients From Receiving Pancreatic Cancer Treatment
- Receptor Agonists With Palonosetron May Reduce Needed Dexamethasone Duration